| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SYNPO |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SYNPO(Synaptopodin)抗体的参考文献示例，格式为虚构内容，仅供参考：
1. **文献名称**: "Synaptopodin regulates actin dynamics in podocytes and protects against proteinuria"
**作者**: Mundel P, et al.
**摘要**: 本研究利用SYNPO抗体通过免疫荧光和Western blot技术，证实Synaptopodin在肾小球足细胞中通过与肌动蛋白结合维持细胞骨架稳定性，其缺失导致实验小鼠出现严重蛋白尿。
2. **文献名称**: "Synaptopodin deficiency exacerbates Alzheimer’s disease pathology in mouse models"
**作者**: Deller T, et al.
**摘要**: 通过SYNPO抗体标记海马神经元突触，研究发现Synaptopodin表达下调与突触可塑性减退相关，敲除SYNPO基因的小鼠呈现更严重的淀粉样斑块沉积和认知功能障碍。
3. **文献名称**: "SYNPO as a biomarker for diabetic nephropathy progression"
**作者**: Zhang Y, et al.
**摘要**: 该研究采用SYNPO抗体对糖尿病肾病患者肾活检组织进行分析，发现Synaptopodin表达水平与肾小球滤过率负相关，提示其可作为糖尿病肾病早期诊断标志物。
4. **文献名称**: "Mechanistic insights into SYNPO-mediated autophagy in podocyte injury"
**作者**: Chen HC, et al.
**摘要**: 通过SYNPO抗体及基因沉默技术，揭示Synaptopodin通过调控mTOR通路影响足细胞自噬活性，其功能障碍导致细胞凋亡并加速肾小球硬化进程。
---
注：以上文献为示例性质，实际研究中请参考真实发表的学术论文。
SYNPO antibodies target synaptopodin, a cytoskeleton-associated protein encoded by the *SYNPO* gene. Synaptopodin is predominantly expressed in renal podocytes and neuronal dendritic spines, playing critical roles in maintaining cell structure and dynamic processes. In podocytes, it interacts with actin filaments and α-actinin-4. regulating foot process architecture and glomerular filtration. Its neuronal counterpart influences synaptic plasticity by modulating actin dynamics in dendritic spines.
SYNPO's association with kidney and neurological disorders has driven research interest. In nephrology, reduced synaptopodin levels correlate with podocyte injury in diseases like focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy, making it a biomarker for glomerular damage. In neuroscience, synaptopodin loss is linked to cognitive deficits in Alzheimer’s disease and schizophrenia.
SYNPO antibodies are vital tools for detecting synaptopodin in immunoassays (e.g., Western blot, immunohistochemistry). They help study protein expression patterns, subcellular localization, and pathophysiological changes in disease models. Commercially available antibodies vary in specificity (e.g., targeting different isoforms: SYNPO-short in neurons, SYNPO-long in podocytes). Validation remains essential due to cross-reactivity risks. Research using SYNPO antibodies continues to unravel its roles in cytoskeletal regulation and disease mechanisms, aiding therapeutic development.
×
